PPI in EMEA’s centralized switch
This article was originally published in The Tan Sheet
The European Medicines Agency's Committee for Medicinal Products for Human Use recommends selling the proton pump inhibitor Pantozol Control (pantoprazole 20 mg) OTC, according to a Feb. 19 release. The Nycomed GmbH product is the first PPI recommended for OTC status across Europe and is the second product recommended for OTC sale through Europe's centralized switch process. The first centrally switched nonprescription product in Europe is GlaxoSmithKline's weight-loss drug alli (1"The Tan Sheet" Oct. 27, 2008, p. 3)
You may also be interested in...
Nycomed is gearing up to launchPantozol Control (pantoprazole 20 mg) later this year when the firm expects an approval for European Union nonprescription marketing authorization
The European Medicines Agency's clearance of GlaxoSmithKline's weight-loss drug alli for nonprescription status across the European Union marks the first success for a centralized Rx-to-OTC switch process
Sigrid Therapeutics co-founder and CEO Sana Alajmovic took time out of what's been an "exciting" year for the company, which makes silica-based products to treat diabetes and related conditions, to speak with Medtech Insight about her experiences as a Bosnia-born working mom in Sweden. This article is the first in a series for International Women's Day.